Zepbound Weight Loss Advantage

Order byBest matchMost fresh

Novo Nordisk, Zepbound and Weight Loss

Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of safety, according to newly released comprehensive tolerability data—findings that Leerink analysts say confirm the GLP-1 drug’s edge in the closely watched market race.

EconoTimes · 2d

Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial

Kalkine Media · 2d

Novo Nordisk Tumbles as Lilly's Zepbound Shows Greater Weight Loss in Trial

· 2d

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study

A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy.

· 1d

This Drug Is Nearly 50 Percent More Effective Than Wegovy

· 2d

Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

Best Life on MSN1d

Weight-Loss Drugs Could Slash Cancer Risk by 41%—Here’s Who Benefits

Participants in a new study who used GLP-1 drugs had a much lower cancer risk than those who had bariatric surgery.

Hosted on MSN1d

Do Medicare, Medicaid cover weight loss drugs? It depends

Wellcare, which offers Medicare Advantage and Medicare Prescription ... Because it is approved to treat sleep apnea, Medicare covers Zepbound for that purpose. It does not cover it solely for weight loss. Patients paying the list price for the medication ...

Wellness companies eager to avoid WeightWatchers’ fate embrace weight-loss drugs

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal regulators crack down on the

Beyond Valuation Ratios: 3 Undervalued Stocks To Buy In May 2025

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Fierce Pharma12d

In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template formularies, Novo said Thursday. CVS Caremark, which forms the eponymous pharmacy chain’s drug benefits unit, is the largest pharmacy benefit manager in the U.S., as Novo pointed out.

Wellness companies embrace weight-loss drugs in bid to avoid fate of WeightWatchers

The weight-loss drug revolution is reshaping the health and wellness industry, forcing companies to adapt or face the same fate as WeightWatchers, which declared bankruptcy this week. The rise in popularity of blockbuster weight-loss medications like Wegovy and Mounjaro has significantly impacted WeightWatchers' business, leading to its downfall.